Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

SAN JOSE, Calif., Jan. 31, 2013 /PRNewswire/ -- Oclaro, Inc. (NASDAQ: OCLR), a provider of optical components, modules and subsystems, today announced the financial results for its second quarter of fiscal year 2013, which ended December 29, 2012.

"Our financial results for the second quarter of fiscal 2013 demonstrate the progress we are making after the merger," said Alain Couder, chairman and CEO. "Our revenues were at the top-end of guidance and we have successfully executed to the planned synergies on schedule. We also took action to strengthen our balance sheet.  Looking ahead, market and economic conditions remain uncertain in a typically softer March quarter. As a result, our efforts will remain focused on reducing operating expenses and improving margin, as well as capitalizing on our new product introductions and strong customer relationships to maximize revenues."

Results for the Second Quarter of Fiscal 2013:Oclaro closed its merger with Opnext, Inc. on July 23, 2012. The financial results for the second quarter of fiscal 2013 include a full quarter of operating results of Opnext. The financial results for the first quarter of fiscal 2013 include approximately ten weeks of operating results of Opnext since the closing of the merger. Results for the second quarter of fiscal 2012 were pre-merger Oclaro and do not include the operating results of Opnext.

  • Revenues were $159.5 million for the second quarter of fiscal 2013, compared with revenues of $148.8 million in the first quarter of fiscal 2013. Pro forma combined revenues for the first quarter of fiscal 2013, including Opnext for the full quarter, were $160.2 million.
  • GAAP gross margin was 13% for the second quarter of fiscal 2013, compared with a GAAP gross margin of 12% in the first quarter of fiscal 2013.
  • Non-GAAP gross margin was 15% for the second quarter of fisca
    '/>"/>

  • SOURCE Oclaro, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
    6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
    7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
    8. Kemwell Announces Successful Pre-NDA US FDA Inspection
    9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
    10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
    (Date:9/2/2014)... ALBANY, New York , September 2, 2014 ... market report published by Transparency Market Research "Latin ... and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility ... Telehealth and Telemedicine, Respiratory Therapy, Infusion Therapy and ... Share, Growth, Trends and Forecast, 2014 - 2020" ...
    (Date:9/2/2014)... España, September 2, 2014 ... fibrilación atrial muestran agentes antitrombóticos no utilizados óptimamente ... -- Las presentaciones de GARFIELD-AF en el ... tratamiento y los resultados de pacientes en riesgo ... --    Los datos de casi ...
    Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11
    ... PediaVision today announced that Loma Linda University,s Vision ... of California to receive the revolutionary new vision ... of Ophthalmology is offering free vision screenings to ... of First 5 Riverside , which invests ...
    ... DURHAM, N.C., Sept. 29, 2011 CoLucid Pharmaceuticals, Inc., ... Chief Executive Officer, Thomas P. Mathers, will be making ... Conference at 9:35 – 10:00 a.m. on Tuesday, October ... Hotel in Tokyo, Japan. The partnering meeting is expected ...
    Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan 2
    (Date:9/2/2014)... San Diego, CA (PRWEB) September 02, 2014 ... guide titled, “Is Group Therapy Right for Me?” The ... joining group therapy or counseling, in addition to common ... in group therapy improve not only from the interventions ... the group and receiving feedback from group members,” says ...
    (Date:9/2/2014)... TCG, a leading government technology strategy and IT consultancy, has ... companies in America for the seventh year in a row, ... 2013, 2012, 2011, 2010, 2009, 2008, and the Inc. 500 ... to 2013, ranking the company at position 3,708 on the ... 635 spots from 2013! More information is on TCG's ...
    (Date:9/2/2014)... The Wm. Jennings Bryan Dorn Veterans Affairs Medical ... meeting for Veterans and their families on September 24. ... provide Veterans with valuable healthcare and benefit information,” said Medical ... a forum where we can gather important input directly from ... will be held 4:45 p.m. to 5:45 p.m. in the ...
    (Date:9/2/2014)... with early-stage breast cancer in California, the percentage undergoing ... although this procedure was not associated with a lower ... to a study in the September 3 issue of ... for the removal of one breast was associated with ... examined in the study. , Randomized trials have demonstrated ...
    (Date:9/2/2014)... (PRWEB) September 02, 2014 Medex ... location of their corporate headquarters in Coral Springs, Fla. ... have exceeded our business development objectives for the 2014 ... Neil Herbst. “Our industry has requested a higher level ... utilization reviews. Medex has delivered, and the industry has ...
    Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
    ... are at a greater risk of catching bird flu, as the ... ,A study on cats in areas where outbreaks have ... than thought. It raises the chilling prospect that the disease could ... human pandemic. And it shows that should bird flu ever break ...
    ... have patented a device, which is capable of the ... by various bacteria, notable amongst which are Salmonella, Campylobacter ... due to food poisoning, as well as of other ... the aim of extending the uses of the device ...
    ... Dengue fever is a viral infection transmitted through the ... patients //never knowing they have been infected. However, in ... tendency triggering the often-fatal Dengue Shock Syndrome. Because some ... the virus from the tropics back to their home ...
    ... rise in pneumonia, bronchitis and other acute respiratory infections in ... the United Nations health agency is sending antibiotics for thousands ... many more from catching the illnesses. ,“Early ... save lives,” UN spokesman Adrian Edwards told a press briefing ...
    ... diuretic drugs should not be recommended as a way to ... caused during pregnancy. It is characterized by high blood pressure, ... urine. The high blood pressure can affect the brain, kidneys, ... in the 1960s to women in order to avoid dangerously ...
    ... of researchers has constructed a model that predicts how ... by airliners. ,The study, "Modeling the Worldwide ... appears in the January issue of the journal PLoS ... the world's largest-scale epidemic simulation of its kind. ...
    Cached Medicine News:Health News:Cat Owners at Risk of Bird Flu 2Health News:A Patented Device for Rapid Diagnosis of Diseases 2Health News:Europeans Developing First-Ever Dengue Fever Vaccine 2Health News:UN Sends Medicine to Afghanistan 2Health News:Avoid Diuretic Pills During Pregnancy 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 3
    The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
    The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
    Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
    Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
    Medicine Products: